Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma — Stella

Home/Smouldering Myeloma/Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma

View on ClinicalTrials.gov

Recruiting

Back to Smouldering Myeloma trials

Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

United Kingdom

Barts Health Trust, London

Nottingham City Hospital, Nottingham

Key details

Phase

Safety & dosing

Sponsor

University College, London

Collaborators

Sanofi, Bristol Myers Squibb Pharmaceuticals Limited

Enrollment target

~63 participants

Started

June 2025

Primary completion

November 2032

Age range

18 Years and older

Last updated August 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.